BerGenBio doses first patient in Phase I trial of ADCT-601
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

BerGenBio doses first patient in Phase I ADCT-601 trial

22 Jan 2019

BerGenBio has dosed the first patient in a Phase I clinical trial assessing the safety, tolerability, pharmacokinetics and anti-tumour efficacy of ADCT-601 for the treatment of patients with advanced solid tumours.

BerGenBio doses first patient in Phase I ADCT-601 trial
A team is making drug capsules in small volume for a clinical trial. Credit: Esther Dyson/Flickr.

BerGenBio has dosed the first patient in a Phase I clinical trial assessing the safety, tolerability, pharmacokinetics and anti-tumour efficacy of ADCT-601 for the treatment of patients with advanced solid tumours.

The open-label, multi-centre, single-arm trial will see BerGenBio enrol around 75 patients with selected tumour types.

BerGenBio license partner ADC Therapeutics will manage and sponsor the trial, which includes a dose-escalation phase followed by a dose-expansion phase.

The trial features a screening period of up to 28 days, a treatment period of three weeks cycle, and a follow-up period of up to two years after the discontinuation of the study drug treatment.

“We look forward to providing updates on the development of BGB149 and ADCT-601 as they progress through Phase I testing.”

Primary objectives of the trial are dose-limiting toxicity and maximum tolerated dose.

The trial’s secondary objectives comprise overall response rate (ORR), disease control rate (DCR), duration of response (DOR), and overall survival (OS).

BerGenBio CEO Richard Godfrey said: “Our focus remains on completing our ongoing oncology Phase II programme with bemcentinib, a first-in-class highly selective oral AXL inhibitor, and start randomised, potentially pivotal trials later this year.

“In the meantime, we look forward to providing updates on the development of BGB149, a therapeutic AXL antibody, and ADCT-601, an anti-AXL ADC, as they progress through Phase I testing.”

BerGenBio’s ADCT-601 drug contains BGB601, a humanised monoclonal antibody that binds to human AXL.